About Us

DalCor is pioneering precision medicine for cardiovascular diseases by tailoring potential new treatments to patients based on their genetic profile.

DalCor is developing dalcetrapib, a unique cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile to maximize clinical benefit.


Our Science

Approximately 20% of people worldwide have the specific genetic profile.


dal-GenE Trial

DalCor is conducting dal-GenE (DAL-301), the first interventional precision medicine cardiovascular outcomes trial. This Phase 3 clinical trial will evaluate the efficacy of dalcetrapib versus placebo to reduce clinical cardiovascular events in 6150 patients post-acute coronary syndrome who have a specific genotype.